Dopamine Receptor D2 (DRD2) Antibody
741€ (1 ml)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Dopamine Receptor D2 (DRD2) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx172153
tested applications
WB, IHC, IF/ICC
Description
This product is currently in development. The lead time for this product may be several months. Please contact us at
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Dopamine Receptor D2 (DRD2) |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Please enquire. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | DRD2,D2A,D2B,dopamine D2 receptor,dopamine receptor 2,D2 receptor,D2R,D2DR |
| Background | Antibody anti-DRD2 |
| Status | RUO |
Descripción
DRD2 is a G protein-coupled receptor belonging to the D2-like receptor family and is highly expressed in the striatum, substantia nigra, and hypothalamus, where it regulates motor control, reward processing, and endocrine function. DRD2 primarily couples to Gi/o proteins, which inhibit adenylate cyclase, reducing cyclic AMP (cAMP) levels and modulating downstream signaling pathways. It exists in two isoforms: the short form (D2S), which functions presynaptically to inhibit dopamine release, and the long form (D2L), which mediates postsynaptic signaling. DRD2 plays a key role in motor control, and its dysfunction is closely linked to Parkinson’s disease, where loss of dopaminergic neurons leads to motor deficits. In neuropsychiatric disorders, DRD2 dysregulation contributes to schizophrenia, bipolar disorder, and drug addiction, where abnormal dopamine signaling disrupts cognition, behavior, and reward mechanisms. Antipsychotic drugs primarily target DRD2 to alleviate symptoms of psychosis by blocking receptor activity. DRD2 also regulates prolactin secretion from the pituitary gland, and its antagonism can cause hyperprolactinemia. Beyond the CNS, DRD2 influences cardiovascular and gastrointestinal function. Given its central role in motor control, reward signaling, and neuropsychiatric disorders, DRD2 remains a critical therapeutic target for Parkinson’s disease, schizophrenia, and substance abuse.
Related Products
Human D2R/DRD2 (Dopamine Receptor D2) ELISA Kit
Ver Producto
DRD2 antibody
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Ver Producto